When Ozempic And Wegovy Fail To Work- Why GLP-1 Drugs Aren’t The Magic Bullet For Everyone
Ozempic and Wegovy have received a lot of publicity as revolutionizing treatment options for obesity. Both medications form a class of GLP-1 receptor agonists, which mimic a hormone in the body called glucagon-like peptide-1 and are involved in the regulation of appetite and blood sugar. Indeed, in initial clinical studies, the majority of those on the drugs lost 15% to 22% of body weight, hence much optimism. For most patients, these medications are underwhelming for about 20% of patients due to minimal weight loss or other challenges.
Take a closer look at why the weight loss drugs may not work for everyone, together with what options exist when they don't deliver the expected outcomes.
While GLP-1 receptor agonists have produced phenomenal responses in a majority of patients, it remains a reality that these drugs work differently for different people. Here's why:
1. Genetic and Hormonal Variability
Weight loss medications interact with complex systems in the body that differ from person to person. Genetics, hormones, and individual brain responses to energy regulation play significant roles in determining how a person responds to drugs like Ozempic and Wegovy.
2. Underlying Medical Conditions
Other conditions, such as sleep apnea, may be prevalent and prevent or delay the achievement of weight loss goals. Prescription drugs like antidepressants, steroids, or contraceptives are other medications that can nullify weight loss medication benefits.
3. Unrealistic Expectations
Often, they come to these medications with enormous hopes; expecting the promised rapid and dramatic weight loss. Progress creates disappointment if it has not stalled. In patients who rigidly follow recommended lifestyle modifications, frustration and disappointment are most common.
For most patients, the effectiveness of GLP-1 receptor agonists is evident within a few weeks of treatment. Weight loss typically begins within a few weeks of initiating therapy and tends to increase with dosage. However, some patients respond very little, if at all, despite strict adherence to their regimen.
For nonresponders, this can feel like a dead end. However, understanding the unique complexities of obesity is essential. This condition stems from brain dysfunction, and the pathways that contribute to weight regulation differ among individuals.
When Ozempic or Wegovy doesn’t yield desired results, there are still many paths to explore:
For example, some patients who don't respond well to one GLP-1 receptor agonist might find success with another drug in the same class. Newer medications, such as Zepbound, target other hormone pathways and seem promising even for those not responsive to earlier drugs.
While there is much to say about newer drugs, older treatments can still be useful and work for some patients. One can also seek the help of a medical provider specializing in obesity treatments in order to identify the best alternatives.
Diet, exercise, sleep, and stress management continue to be integral components of any weight loss program. New changes may be small but can make an enormous difference in one's health and success.
It is a complex disorder, and most patients should receive a multidisciplinary treatment. Collaboration with an obesity-aware doctor may mean access to tailored treatment plans, ranging from psychological support all the way to metabolic testing, and many others.
For others, side effects like nausea, vomiting, or diarrhea hinder them from continuing with these drugs. These symptoms often reduce as the body becomes accustomed, but for some, they might be severe enough to stop treatment altogether. In those instances, alternative drugs or procedures become vital to find.
Another largely unexplored area relates to GLP-1 drugs' long-term effects on the brain's regulation of hunger and satiety. Although GLP-1 drugs suppress appetite and can lead to effective weight loss, emerging research suggests that they may also affect brain reward mechanisms, changing the way patients experience foods.
This aspect could prove of paramount significance in the future treatment of obesity. Perhaps GLP-1 receptor agonists do indeed affect and rewire the brain's reward pathways and will thus provide sustained benefits beyond discontinuation. However, more research is required to understand this phenomenon fully.
While for many, Ozempic and Wegovy have revolutionized obesity treatment, these are certainly not a one size fits all. Nonresponders need not lose hope- alternative strategies and medications abound. A consultation with an obesity expert healthcare provider is essential to put together a comprehensive, tailored treatment plan.
The route toward effective weight loss may be challenging, but with the evolution of obesity medicine and a better understanding of individual needs, there is a path forward for everyone.
Credit: iStock
Down Syndrome is a common genetic disorder in which an extra copy of chromosome 21 (Trisomy 21) causes mild-to-moderate intellectual disabilities, developmental delays, and characteristic physical traits.
Every year, World Down Syndrome Day is observed on March 21 every year to raise public awareness about the condition, which deserves more than medical care.
The theme for World Down Syndrome Day 2026 is 'Together Against Loneliness,’ and it focuses on raising awareness of how loneliness disproportionately affects people with Down syndrome and other intellectual disabilities, as well as their families.
According to the UN data, the estimated incidence of Down syndrome is between 1 in 1,000 -- 1 in 1,100 live births worldwide. Each year, approximately 3,000 to 5,000 children are born with this chromosome disorder.
In India, about 30,000 babies are born with Down syndrome every year.
While Down Syndrome is not preventable, in a video post on the social media platform X, Dr. Neerja Gupta from AIIMS Delhi highlighted the importance of early detection, screening, and long-term support for better outcomes.
Dr. Gupta, Professor, Division of Genetics at AIIMS's Department of Pediatrics, also explained the causes of the condition and shared tests that can help eliminate the risks in future babies.
“Down syndrome is a common chromosomal disorder in which chromosome 21 is present in three copies instead of two. Normally, every human cell has 46 chromosomes. However, in Down syndrome, there are 47 chromosomes because the 21st chromosome is present in three copies instead of two,” she said.
Due to the increase in the number of chromosomes, the child may:
"The sooner we can catch them, the earlier we can begin the intervention, resulting in better health outcomes," Dr Gupta said.
Down syndrome can occur in three types, depending on how the extra copy of chromosome 21 is present. In all cases, chromosome 21 appears in three copies, but this can happen in different ways.
"As the mother’s age increases, the risk of Down syndrome also increases. Today, there are several prenatal tests available to detect this condition during pregnancy," the expert said.
"In this, the DNA is seen in the fetal baby's stomach through the mother's blood, to check whether the chromosomal copies are in the right number or not," she said.
The expert noted that this screening test is highly accurate, but if the results indicate a high risk, diagnostic testing of the fetus is recommended.
Credit: Canva
Cosmetic treatments are no longer rare or exclusive. A quick search online reveals hundreds of options promising smoother skin, sharper features, or younger-looking results. Walk through any city, and you’ll find salons and aesthetic studios advertising fillers, lasers, chemical peels, and anti-ageing injections. On the surface, it all looks routine. But for many doctors, this growing trend has also raised an uncomfortable question: who is actually performing these procedures?
The skin is considered a cosmetic surface that can be polished or fixed quickly. In reality, skin is the largest organ of the body and is closely related to other deeper structures like the blood vessels, nerves, and muscles. Procedures that alter or inject into these layers require medical knowledge and technical training.
When carried out by individuals without proper qualifications, even treatments marketed as “simple” can turn risky.
In recent years, cosmetic procedures have moved far beyond hospitals and specialised clinics. Many services are now offered in beauty salons or small aesthetic centres that operate with very little medical know-how.
The treatments themselves may sound harmless: lip fillers, Botox injections, laser resurfacing, or skin tightening.
Unfortunately, the procedures done are not merely surface-level. For example, injectables are not something done without considering the underlying structures and related anatomy. A small error or poor technique can result in uneven, unbalanced results, or prolonged swelling or more serious complications such as blocked blood vessels.
Laser treatments also require expertise. Different skin types react differently to energy-based devices. Incorrect settings can result in burns, pigmentation changes, or scarring that may take months to correct.
Qualified dermatologists and plastic surgeons approach cosmetic procedures with a very different mindset. The process rarely begins with the treatment itself. It begins with evaluation.
A trained specialist looks at the patient’s medical history, skin condition, lifestyle habits, and expectations before recommending any intervention. Sometimes the safest recommendation is to delay a procedure or choose a less aggressive approach.
Patients should also take a moment to verify the doctor's qualifications to perform the procedure. A qualified plastic surgeon typically holds an MCh or DNB degree in plastic surgery, whereas a dermatologist holds an MD or DNB in Dermatology. The risks of choosing a provider on the basis of cost or accessibility can expose patients to unnecessary risks.
Medical training also prepares specialists to recognise complications early and manage them effectively. Even well-performed procedures can occasionally cause reactions. The difference lies in how quickly those issues are identified and treated.
Lower prices and easy accessibility often attract people toward unregulated services. What many do not realise is that fixing a poorly performed cosmetic procedure can be far more complex than the original treatment.
Corrective procedures may involve dissolving fillers, repairing damaged skin, or undergoing additional medical care to restore normal appearance. Apart from the financial cost, these situations can also affect confidence and emotional well-being.
Cosmetic procedures can be safe and effective when performed by trained medical professionals. Patients should feel comfortable asking about qualifications, experience, and the type of equipment being used. A responsible practitioner will always prioritise safety, proper consultation, and realistic expectations.
Aesthetic treatments may focus on appearance, but the responsibility behind them is medical. Your skin deserves expertise, careful judgement, and the assurance that every step is taken with your health in mind.
An estimated 4.9 million children died before reaching their fifth birthday in 2024, including 2.3 million newborns, according to the latest United Nations report on global child mortality. The findings were released in the report Levels and Trends in Child Mortality, which examines the leading causes of deaths among children worldwide.
The report notes that many of these deaths could have been prevented through simple and affordable health measures. Access to quality healthcare, timely treatment, vaccination, and better nutrition remain key factors in reducing child deaths.
Over the past two decades, the world has made significant progress. Global under five deaths have dropped by more than half since 2000. However, the pace of improvement has slowed in recent years. Since 2015, the rate of decline in child mortality has fallen by more than 60 percent, raising concerns among health experts.
Despite global challenges, India has made notable progress in improving child survival rates through sustained public health efforts.
According to the United Nations Inter Agency Group for Child Mortality Estimation (UNIGME) Report 2025, India has steadily reduced deaths among newborns and young children over the past decades. The Union Health Ministry said the country has played an important role in lowering child mortality across South Asia.
India’s Neonatal Mortality Rate, which measures deaths within the first 28 days of life, has seen a major decline. In 1990, the rate stood at 57 deaths per 1,000 live births. By 2024, it had dropped to 17.
A similar trend was seen in the Under Five Mortality Rate. In 1990, India recorded 127 deaths per 1,000 live births among children under five. By 2024, that number had fallen sharply to 27.
Health officials attribute this progress to targeted public health programmes, improved hospital deliveries, and wider vaccination coverage.
The report highlights that several preventable health conditions continue to drive child deaths across the world.
For the first time, the report estimated deaths directly caused by severe acute malnutrition. It found that more than 100,000 children aged between one month and five years died due to severe malnutrition in 2024.
Experts believe the real impact may be even higher because malnutrition often weakens the immune system. This makes children more vulnerable to common infections such as pneumonia, diarrhea, and malaria, which can become life threatening.
Some countries reporting high numbers of malnutrition related deaths include Pakistan, Somalia, and Sudan.
Nearly half of all deaths among children under five occur during the newborn stage. This reflects slower progress in preventing deaths around the time of birth.
The leading causes of newborn deaths include complications related to premature birth, which account for about 36 percent of cases. Problems during labor and delivery contribute to around 21 percent of deaths.
Other important causes include infections such as neonatal sepsis and certain birth defects.
After the first month of life, infectious diseases remain the main threats to children’s survival. Malaria, diarrhea, and pneumonia are among the biggest causes of death.
The report also points out that global funding for maternal and child health programmes is facing increasing pressure. This could slow progress in reducing child deaths in the coming years.
Experts stress that investing in child health remains one of the most effective public health strategies. Basic interventions such as vaccination, treatment for severe malnutrition, and skilled care during childbirth can save millions of lives.
According to the report, such measures not only improve health outcomes but also strengthen economies by creating healthier and more productive populations.
© 2024 Bennett, Coleman & Company Limited